ArticleMolecular therapy oncolytics2022

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.

Jessica Wenthe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.